Loading clinical trials...
Loading clinical trials...
The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe gl...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AbbVie
NCT06481475 · Moderate to Severe Glabellar Lines
NCT06205797 · Glabellar Lines
NCT07321834 · Glabellar Lines
NCT06583486 · Moderate to Severe Glabellar Lines
NCT07398755 · Glabellar Lines, Midface Volume Deficiency, and more
Investigate MD /ID# 270771
Scottsdale, Arizona
Eye Research Foundation /ID# 270827
Newport Beach, California
Marcus Facial Plastic Surgery /ID# 270770
Redondo Beach, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions